Analytical Champions: Sarah O’Keeffe

• November 10, 2026

FDA expands talazoparib use in prostate cancer

The combination with enzalutamide reduced the risk of radiographic progression or death by 52% .

• by Mouj Hijazi

• October 27, 2026

• 3 min

How Genomics Is Personalizing Drug Discovery

Regeneron Genetics Center’s Luca Lotta explains how population-scale genetic evidence can reveal more promising drug targets and open new possibilities for disease prevention

• by Mouj Hijazi

• October 20, 2026

• 8 min

Beyond Statistical Significance—What Did EMERGE Really Tell Us About Early Metformin?

• by Karla Hemming, Stephan D. Fihn

• November 3, 2026